Skip to main content
Clinical Trials/NCT06117293
NCT06117293
Recruiting
Not Applicable

Safety and Efficacy Evaluation of the Mosaic Ultra Device

LUTRONIC Corporation3 sites in 1 country200 target enrollmentStarted: February 21, 2023Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
200
Locations
3
Primary Endpoint
Photographic Assessment

Overview

Brief Summary

Evaluate the Safety and Efficacy of the Mosaic Ultra 1550nm system for the treatment of skin tone and texture, facial rejuvenation, photoaging, wrinkles, scars, stretch marks, acne vulgaris and hair loss.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Non-smoking, Male or Female
  • Age 18 - 60 years old
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated.
  • Participants who are willing and able to comply with all study participation requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
  • OPTIONAL - Participants who are willing to undergo biopsies.

Exclusion Criteria

  • Previous surgical or cosmetic procedure to the target area in the last 6 to 12 months that could interfere with the treatment procedure
  • A study participant must not be pregnant or have been pregnant in the last 3 months
  • A recent history of smoking (6 months)
  • Presence of an active skin disease or condition that may affect wound healing (ie. diabetes myelitis; connective tissue disease; radiation therapy; or chemotherapy)
  • Seizure disorder caused by bright light
  • A history of thrombophlebitis
  • A history of acute infections
  • A history of heart failure
  • Cancer, malignant disease, skin pathology, condition, or allergic reactions that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during, or after treatments
  • Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E, or anti-inflammatories within 2 weeks prior to treatment

Outcomes

Primary Outcomes

Photographic Assessment

Time Frame: 90-day Follow-Up

Evaluation of Randomized Before Treatment and 3-Month Follow-Up Images by Blinded Evaluators

Secondary Outcomes

  • Safety Assessment(up to 90 days post final treatment)
  • Physician Satisfaction(30-day and 90-day Follow-Up)
  • Physician Clinical Global Aesthetic Improvement Scale(30-day and 90-day Follow-Up)
  • Coagulation Zone Measurements(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)
  • Tissue Reepithelization(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)
  • Subject Satisfaction(30-day and 90-day Follow-Up)
  • Subject Clinical Global Aesthetic Improvement Scale(30-day and 90-day Follow-Up)
  • Epidermal Inflammatory Response(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)
  • Dermal Inflammatory Response(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials